American journal of ophthalmology
-
Foreign body sensation in four patients was caused by particles from a cosmetic facial scrub that contained small plastic spheres designed to abrade the skin. The particles were lodged in the superior palpebral conjunctiva 2 to 3 mm from the eyelid margin. ⋯ Removal of the particles eliminated the foreign body sensation and there were no lasting deleterious effects.
-
Randomized Controlled Trial Clinical Trial
Response of Bitot's spots to a single oral 100,000- or 200,000-IU dose of vitamin A.
A randomized, controlled clinical trial was conducted in Indonesia to study the response of Bitot's spots to a 100,000-IU dose of vitamin A, which is known to be associated with fewer acute side effects than the currently recommended 200,000-IU dose. ⋯ Although either a 100,000- or 200,000-IU dose of vitamin A is similarly effective in healing Bitot's spots, a 200,000-IU dose provides longer protection. This benefit justifies the higher rates of transient mild side effects associated with the 200,000-IU dose. The current 200,000-IU dose of vitamin A recommended by the World Health Organization for prophylactic dosing should not be reduced.
-
Randomized Controlled Trial Clinical Trial
Decrease in normal human corneal sensitivity with topical diclofenac sodium.
We tested the effect of topical diclofenac sodium on corneal sensitivity in the human eye. Corneal sensitivity was measured in ten adult subjects with the Cochet-Bonnet esthesiometer before, and immediately after, applying one drop of diclofenac sodium 0.1% in one eye and one drop of diclofenac vehicle in the other eye. Application was repeated every five minutes for 20 minutes; then no more drops were applied, and corneal sensitivity was measured every 15 minutes until sensitivity measurements returned to baseline levels. ⋯ The effect of diclofenac sodium increased as additional drops were administered. After the drug instillation was stopped, corneal sensitivity returned to baseline measurements within less than an hour in all the subjects. Diclofenac sodium substantially lowers sensitivity in normal, unoperated-on human corneas; the vehicle has no measurable effect on sensitivity.
-
We analyzed data on 1,108 patients (1,229 eyes) with various types of retinal vein occlusion. Retinal vein occlusion was classified into six distinct clinical types: (I) nonischemic and (II) ischemic central retinal vein occlusion, (III) nonischemic and (IV) ischemic hemicentral retinal vein occlusion, and (V) major and (VI) macular branch retinal vein occlusion. ⋯ The cumulative probability of developing a second episode of the same or a different type of retinal vein occlusion in the same eye was 0.9% within two years and 2.5% within four years, and in the fellow eye was 7.7% and 11.9%, respectively. The cumulative probability of conversion of nonischemic to ischemic central retinal vein occlusion at six months and 18 months was 13.2% and 18.6%, respectively, in persons 65 years of age or older and 6.7% and 8.1%, respectively, in persons 45 to 64 years of age.